HAE Maintained by Mizuho -- Price Target Raised to $140
Mizuho maintained an Outperform rating for Haemonetics (HAE) and raised its price target to $140 from $95, a 47.37% increase. The stock is currently priced at $116.90, which is 35.3% over its GF Value™ of $86.42, according to GuruFocus. HAE has a GF Score™ of 76/100, with strengths in profitability and growth but concerns about valuation. Seven gurus hold positions in HAE, with five increasing their stakes recently.
How this was made
The 30-second read
Why it matters
The new $140 target may attract new buying interest, but valuation concerns could temper the rally.
Market read
Analyst target raise is the primary catalyst; the news is modest but actionable for short‑term traders.
What to watch
High P/E ratio and valuation rank could limit upside despite the target raise.
Background
Haemonetics operates in blood‑management devices, a niche within healthcare. The analyst upgrade reflects confidence in its growth prospects.
Ticker impact
Mizuho raised its price target for Haemonetics to $140 and maintained an Outperform rating, indicating fresh analyst optimism.
likely upward pressure as investors price in the higher target.
Analyst upgrades often lead to short‑term buying interest, especially when the new target is 47% above the prior level.
Market effects
May boost sentiment toward the broader medical‑devices sector as analysts see growth potential.
Limited to U.S. equities; no broader regional effect.
Low; impact confined to Haemonetics and its immediate peers.
Counterpoint
The stock appears overvalued at a 35% premium to its intrinsic value, suggesting caution.
Key entities
- analystMizuho
Maintained Outperform rating and raised price target.
- companyHaemonetics Corp
Medical‑devices firm focused on blood and plasma collection.
